- ISIN
- CA6823108759
- CUSIP
- 682310875
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 8, 1999
Highlights
- Market Cap
- $105.66M
- Enterprise Value
- $100.84M
- EPS (TTM)
- -$0.31
- EBITDA (TTM)
- -$31.10M
- Year Range
- $0.69 - $1.51
- ROA (TTM)
- -383.72%
- ROE (TTM)
- 610.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ONCY Performance Chart
Oncolytics Biotech Inc (ONCY) is up 7.7% since the beginning of the year. At $1 per share, ONCY is trading 37.7% below its 52-week high of $2. Investors who bought $1,000 worth of ONCY shares 5 years ago would now be looking at an investment worth $317.
Loading charts...
Returns By Period
Oncolytics Biotech Inc (ONCY) has returned 7.65% so far this year and 47.71% over the past 12 months.
Oncolytics Biotech Inc
- 1D
- 2.58%
- 1M
- 16.23%
- YTD
- 7.65%
- 6M
- -1.37%
- 1Y
- 47.71%
- 3Y*
- -29.97%
- 5Y*
- -20.54%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
ONCY Monthly Returns History
Based on dividend-adjusted daily data since May 31, 2018, ONCY's average daily return is +0.05%, while the average monthly return is +2.72%. At this rate, an investment would double in approximately 2.2 years.
Historically, 35% of months were positive and 65% were negative. The best month was Dec 2019 with a return of +325.0%, while the worst month was Aug 2019 at -55.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.
On a daily basis, ONCY closed higher 42% of trading days. The best single day was Dec 26, 2019 with a return of +54.1%, while the worst single day was Aug 14, 2019 at -35.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.21% | 15.22% | -24.88% | 3.68% | 18.18% | -9.53% | 7.65% | ||||||
| 2025 | -20.22% | -9.36% | -16.77% | 3.78% | -40.43% | 127.35% | 31.95% | 1.96% | 34.62% | -15.00% | -16.24% | -12.32% | -4.36% |
| 2024 | -11.85% | -4.20% | -7.02% | 4.72% | -3.60% | -7.48% | 5.05% | -7.79% | -9.18% | 32.03% | -19.13% | -1.74% | -32.31% |
| 2023 | 9.20% | -14.04% | -21.57% | 21.66% | 10.97% | 60.49% | -3.08% | -9.13% | -4.80% | -23.85% | -12.65% | -6.90% | -17.18% |
| 2022 | 36.69% | -10.53% | -7.06% | -16.46% | -11.36% | -13.68% | 13.58% | 25.15% | -14.33% | 2.44% | 39.68% | -7.39% | 17.27% |
| 2021 | 5.04% | 28.40% | 18.69% | -19.95% | 0.00% | -9.18% | -16.25% | -0.43% | -9.52% | -2.39% | -17.16% | -17.75% | -41.60% |
Benchmark Metrics
Oncolytics Biotech Inc has an annualized alpha of -3.19%, beta of 1.19, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 31, 2018.
- This stock participated in 190.10% of S&P 500 Index downside but only 75.84% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -3.19%
- Beta
- 1.19
- R²
- 0.06
- Upside Capture
- 75.84%
- Downside Capture
- 190.10%
Return for Risk
Risk / Return Rank
ONCY ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Oncolytics Biotech Inc (ONCY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ONCY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.27 | ||
| Sortino ratioReturn per unit of downside risk | -0.89 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.32 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 1.06 | 2.46 | -1.40 |
| Martin ratioReturn relative to average drawdown | 1.74 | 10.92 | -9.18 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Oncolytics Biotech Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Oncolytics Biotech Inc was 95.80%, occurring on Jun 5, 2025. The portfolio has not yet recovered.
The current Oncolytics Biotech Inc drawdown is 88.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -95.80%Jun 2025 | 7y 7d | — | 8y 26dMay 2018 - now |
Drawdown Indicators
| ONCY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.80% | -56.78% | -39.02% |
Max Drawdown (1Y)Largest decline over 1 year | -45.42% | -9.10% | -36.32% |
Max Drawdown (3Y)Largest decline over 3 years | -89.73% | -18.90% | -70.83% |
Max Drawdown (5Y)Largest decline over 5 years | -89.73% | -25.43% | -64.30% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -88.12% | -3.21% | -84.91% |
Average DrawdownAverage peak-to-trough decline | -77.82% | -10.71% | -67.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.52% | 2.04% | +25.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Oncolytics Biotech Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Oncolytics Biotech Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ONCY
Add Oncolytics Biotech Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ONCY